|
KMID : 1011720220150010042
|
|
International Journal of Thyroidology
2022 Volume.15 No. 1 p.42 ~ p.48
|
|
|
Lung Related Complications in Patients with Advanced Thyroid Cancer during Lenvatinib Therapy: Case Series and Literature Review
|
|
Yoon Jee-Hee
Hong A-Ram
Kim Hee-Kyung
Kang Ho-Cheol
|
|
|
Abstract
|
|
|
|
Lenvatinib prolongs the survival of patients with advanced thyroid cancer. At initiation of lenvatinib therapy, advanced thyroid cancer patients frequently have lung metastasis and are vulnerable to pulmonary complications due to concealed lung damage caused by previous therapies including radioactive iodine (RAI) therapy. Among 24 patients treated with lenvatinib, pulmonary events were observed in three patients with lung metastasis, including one with interstitial lung disease (ILD) and two with pneumothorax. One patient who was previously treated with 750 mCi RAI developed uncontrolled ILD after lenvatinib therapy and died of respiratory failure. Two pneumothorax cases had previous cavitation of metastatic lung nodules. Pneumothorax resolved spontaneously in both patients. Pulmonary events in patients with lung metastases treated with lenvatinib are uncommon and manageable in most cases, but may be fatal if detection and management are delayed. Special attention should be given to patients with lung metastasis treated with high cumulative dose of RAI therapy or cavitary changes that develop after lenvatinib therapy.
|
|
|
KEYWORD
|
|
|
Advanced thyroid cancer, Tyrosine kinase inhibitor (TKI), Lenvatinib, Pneumothorax
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|